(Q42675644)

4 November 2017

title

Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics (English)

1 reference

4 November 2017

0 references

1 reference

William Jeffery Sandborn

series ordinal

1

object named as

William J Sandborn

1 reference

4 November 2017

Jean-Frédéric Colombel

series ordinal

2

object named as

Jean-Frédéric Colombel

1 reference

4 November 2017

3

Stefan Schreiber

1 reference

4 November 2017

4

Scott E Plevy

1 reference

4 November 2017

7

Jingdong Chao

1 reference

4 November 2017

8

Parvez Mulani

1 reference

4 November 2017

Paul F Pollack

5

1 reference

4 November 2017

Anne M Robinson

series ordinal

6

1 reference

4 November 2017

publication date

1 January 2011

1 reference

Inflammatory Bowel Diseases

4 November 2017

published in

1 reference

4 November 2017

volume

17

1 reference

4 November 2017

issue

1

1 reference

4 November 2017

page(s)

141-151

1 reference

Inflammatory bowel disease: cause and immunobiology

4 November 2017

cites work

1 reference

Inflammatory bowel disease: clinical aspects and established and evolving therapies

21 January 2018

1 reference

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial

21 January 2018

1 reference

Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study

21 January 2018

1 reference

Adalimumab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group

21 January 2018

1 reference

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IBD.21328

1 reference

4 November 2017

1 reference